Novo's mistake was underestimating what kind of success they had on hand, then not having the preparedness to accelerate production to meet the surge in demand.
Technically, not being able to properly estimate how successful their glp1 jab would be, could be excused, since they were the main player entering into unfamiliar territory. But not being able to capitalise on their early lead and step up production is inexcusable. This slip up pushed the US government to allow competitors to step in to make up the shortfall, and these players exploited loopholes to continue producing even when Novo started to catch up.
Similarly, Eli Lilly took the chance to produce their glp1 jab, then got the formal USA approval, to properly compete and further cut into Novo's market share.
I believe that such drugs prey on human shallowness and the neverending insecurity that people have about their outlook. Glp1 may be the wonder drug for chronic obesity or diabetes, but it should not be a recreational drug for any Tom, Dick and Harry who they do not like how they look and want to be thinner.
The slippery slope of people who are healthy enough, but cannot push themselves to be more active, then resorting to the glp1 jabs/drugs to lose weight, then not knowing when to stop and becoming unhealthily thin would be the next big headache. There simply has to be more controls in place, without which, these manufacturers would be making big money off the backs of people's insecurity of their bodies.
So yes, there is more room to grow, at the unnecessary expense of people's health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
